

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

THURSDAY, SEPT 18 • 4 – 5 PM CT • REGENCY D (BALLROOM LEVEL) / HYBRID

- **SWOG CTP overview**
 - Joint study development process
 - Scientific areas of interest
 - Types of trials
- **Site logistics: operations & data management**
 - Feasibility survey outreach and site selection
 - Site funding and contracts
- **Updates from behind the scenes**
 - From Group Statistician Michael LeBlanc, PhD
 - From the trenches – site ORP report
- **SWOG CTP trials in development:**
 - **21CTP.Breast01 (MONITOR):** Phase II platform trial using circulating tumor DNA to monitor treatment response in HR+, HER2- metastatic breast cancer
 - **25CTP.Breast02 (SAVE):** Randomized trial of second line adjuvant therapy for molecular relapse in stage I-III hormone receptor positive, HER2 negative breast cancer
 - **26CTP.Leuk02:** Randomized phase IV trial for treatment-naïve, cytopenic myelofibrosis

• **SWOG CTP active trials**

- **21CTP.Leuk01:** Phase II trial for patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- **21CTP.HN01 (CAPT-HN):** Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies



To apply to open either study, complete its feasibility survey at swogctp.org/trials.

- Accrual completed: TROPION Breast 03 FDA registration trial
- Novel CTP projects and other collaborative opportunities

All are invited!

Learn more: swogctp.org

Email us: CTP@swog.org